References

Pancreatectomy for Metastatic Disease: A Systematic Review

10.1016/j.ejso.2013.12.022 · 2014 · External reference

Surgery for Metastasis to the Pancreas: Systematic Review of Observational Cohort Studies

10.1016/j.hpb.2025.07.003 · 2025 · External reference

A Pooled Analysis of Pancreatic Resection for Metastatic Renal Cell Carcinoma

10.3389/fonc.2024.1442256 · 2024 · External reference

Systematic Review of Pancreatic Surgery for Metastatic Renal Cell Carcinoma

10.1002/bjs.6606 · 2009 · External reference

Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

10.1056/nejmoa2035716 · 2021 · External reference

Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

10.6004/jnccn.2021.0017 · 2021 · External reference

International Consensus on Definition and Criteria of Borderline Resectable Pancreatic Ductal Adenocarcinoma 2017

10.1016/j.pan.2017.11.011 · 2018 · External reference

Metastatic Tumors to the Pancreas: A Systematic Review and Meta‐Analysis

2016 · External reference

Surgical Resection for Metastatic Tumors in the Pancreas: A Single‐Center Experience and Systematic Review

10.1245/s10434-019-07258-2 · 2019 · External reference

Lenvatinib Plus Pembrolizumab Versus Sunitinib as First‐Line Treatment of Patients With Advanced Renal Cell Carcinoma (CLEAR): Extended Follow‐Up From the Phase 3, Randomised, Open‐Label Study

10.1016/s1470-2045(23)00049-9 · 2023 · External reference

Lenvatinib Plus Pembrolizumab Versus Sunitinib for Advanced Renal Cell Carcinoma: Japanese Patients From the CLEAR Study

10.1002/cam4.5483 · 2023 · External reference

Clinical Outcomes by Baseline Metastases in Patients With Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab Versus Sunitinib: Post Hoc Analysis of the CLEAR Trial

10.1002/ijc.35288 · 2025 · External reference

The Impact of Cytoreductive Nephrectomy on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Immunotherapy: An Evidence‐Based Analysis of Comparative Outcomes

10.3389/fimmu.2023.1132466 · 2023 · External reference

Perioperative Therapy in Renal Cancer in the Era of Immune Checkpoint Inhibitor Therapy

10.1097/mou.0000000000000868 · 2021 · External reference

Pathological Response and Outcomes in Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Immunotherapy‐Based Therapies and Undergoing Deferred Cytoreductive Nephrectomy (CN)

10.1016/j.clgc.2024.102177 · 2024 · External reference

Downstaging and Pathological Complete Response of Locally Recurrent Sarcomatoid Renal Cell Carcinoma Under Pembrolizumab and Lenvatinib: A Case Report and Review of Literature

10.1159/000534000 · 2023 · External reference

Pathological Eradication of Recurrent Metastatic Renal Cell Carcinoma With Sarcomatoid Component by Nivolumab Plus Ipilimumab Combination Therapy

10.1007/s13691-021-00501-2 · 2021 · External reference

Case Report: Locally Invasive Thyroid Metastases From Renal Cell Carcinoma: Surgery After Neoadjuvant Therapy

10.3389/fonc.2025.1543060 · 2025 · External reference